
Prajwal Dhakal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3529412/publications.pdf Version: 2024-02-01



ΟσλινιλΙ ΠΗΛΚΛΙ

#	Article	IF	CITATIONS
1	Disparity in Utilization of Multiagent Therapy for Acute Promyelocytic Leukemia in the United States. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 319-325.	0.2	2
2	Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age?. Future Oncology, 2022, 18, 311-321.	1.1	13
3	Determinants of ten-year overall survival of acute myeloid leukemia: a large national cancer database analysis. Leukemia and Lymphoma, 2022, 63, 939-945.	0.6	1
4	Impact of Insurance on Overall Survival in Acute Lymphoblastic Leukemia: A SEER Database Study. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.2	2
5	Association of insurance types and outcomes in acute promyelocytic leukemia. Leukemia and Lymphoma, 2022, 63, 2627-2635.	0.6	1
6	Effect of Age and Socioeconomic Factors in the Utilization of Chemotherapy in Acute Lymphoblastic Leukemia (ALL): A SEER Database Study of 16,196 Patients. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e907-e914.	0.2	3
7	Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorableâ€risk acute myeloid leukemia. American Journal of Hematology, 2021, 96, E59-E63.	2.0	11
8	Development and validation of the Therapy Preference Scale to understand patients´ systemic cancer treatmentÂpreferences. Future Oncology, 2021, 17, 37-44.	1.1	2
9	Early mortality and overall survival in acute promyelocytic leukemia: do real-world data match results of the clinical trials?. Leukemia and Lymphoma, 2021, 62, 1949-1957.	0.6	9
10	Disparity in utilization of multiagent therapy for acute promyelocytic leukemia (APL): A large National Cancer Database (NCDB) analysis Journal of Clinical Oncology, 2021, 39, 6587-6587.	0.8	0
11	Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?. Leukemia and Lymphoma, 2020, 61, 7-17.	0.6	6
12	Effects of Obesity on Overall Survival of Adults With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e131-e136.	0.2	10
13	Treatment Strategies for Therapy-related Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 147-155.	0.2	10
14	Usefulness of Charlson Comorbidity Index to Predict Early Mortality and Overall Survival in Older Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 804-812.e8.	0.2	19
15	Do USMLE steps, and ITE score predict the American Board of Internal Medicine Certifying Exam results?. BMC Medical Education, 2020, 20, 79.	1.0	23
16	Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia. Leukemia and Lymphoma, 2020, 61, 1702-1708.	0.6	9
17	Effects of Distance From Academic Cancer Center on Overall Survival of Acute Myeloid Leukemia: Retrospective Analysis of Treated Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e685-e690.	0.2	6
18	An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants. Advances in Hematology, 2020, 2020, 1-10.	0.6	24

Prajwal Dhakal

#	Article	IF	CITATIONS
19	Understanding therapy preferences of cancer patients with the use of therapy preference scale Journal of Clinical Oncology, 2020, 38, e24186-e24186.	0.8	1
20	Usefulness of Charlson comorbidity index (CCI) to predict early mortality and overall survival (OS) in acute myeloid leukemia (AML) Journal of Clinical Oncology, 2020, 38, e19129-e19129.	0.8	0
21	Evaluation of high-dose methotrexate serum concentration requirement for discharge Journal of Clinical Oncology, 2020, 38, e19204-e19204.	0.8	0
22	Anatomical Variations in Circle of Willis in Patients Undergoing CT Cerebral Angiography in a Tertiary Hospital in Nepal: A Descriptive Cross-sectional Study. Journal of the Nepal Medical Association, 2020, 58, 1065-1068.	0.1	2
23	Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML). Blood, 2020, 136, 41-42.	0.6	1
24	Early Mortality and Overall Survival in Acute Promyelocytic Leukemia: Do Real-World Data Match Results of the Clinical Trials?. Blood, 2020, 136, 13-14.	0.6	0
25	Initial management of immune thrombocytopaenia in adults based on risk stratification. Postgraduate Medical Journal, 2019, 95, 558-562.	0.9	2
26	Effects of center type and socioeconomic factors on early mortality and overall survival of diffuse large B-cell lymphoma. Future Oncology, 2019, 15, 2113-2124.	1.1	7
27	Overutilisation of imaging studies for diagnosis of pulmonary embolism: are we following the guidelines?. Postgraduate Medical Journal, 2019, 95, 420-424.	0.9	22
28	Effectiveness of Sequential Compression Devices in Prevention of Venous Thromboembolism in Medically III Hospitalized Patients: A Retrospective Cohort Study. Turkish Journal of Haematology, 2019, 36, 193-198.	0.2	3
29	Immune-related adverse events in melanoma: A nationwide analysis 2016 Journal of Clinical Oncology, 2019, 37, e18253-e18253.	0.8	Ο
30	Effects of obesity on overall survival (OS) of patients with acute myeloid leukemia (AML) Journal of Clinical Oncology, 2019, 37, e18510-e18510.	0.8	0
31	Therapy preference scale: A novel questionnaire to understand patients' preferences of cancer treatment Journal of Clinical Oncology, 2019, 37, e23179-e23179.	0.8	1
32	Pemetrexed Induced Life-threatening Anaphylaxis. Cureus, 2019, 11, e5514.	0.2	1
33	Atypical chronic myeloid leukemia: a rare entity with management challenges. Future Oncology, 2018, 14, 177-185.	1.1	16
34	Spontaneous tumour lysis syndrome in small cell lung cancer: a rare phenomenon. BMJ Case Reports, 2018, 2018, bcr-2018-224512.	0.2	8
35	CAN WE Predict Risk Factors of Venous Thromboembolism Among Cancer Inpatients?. Blood, 2018, 132, 5871-5871.	0.6	1
36	Serendipitous Discovery of Factor VII Deficiency and the Ensuing Dilemma. Mædica, 2018, 13, 71-73.	0.4	0

Prajwal Dhakal

#	Article	IF	CITATIONS
37	Eculizumab in Transplant-Associated Thrombotic Microangiopathy. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 175-180.	0.7	48
38	An Algorithmic Approach to Management of Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 511-517.	0.7	1
39	Chylothorax: A Review of Management Options. Clinical Pulmonary Medicine, 2017, 24, 66-68.	0.3	2
40	Central nervous system complications after allogeneic hematopoietic stem cell transplantation. Future Oncology, 2017, 13, 2297-2312.	1.1	13
41	Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 410-415.	0.7	47
42	Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy?. Bone Marrow Transplantation, 2017, 52, 352-356.	1.3	25
43	Renal Cancer in Recipients of Kidney Transplant. Rare Tumors, 2017, 9, 9-13.	0.3	9
44	Use of Digital Technology to Optimize Functional Status in an Older Patient With Myelodysplastic Syndrome. Journal of Oncology Practice, 2017, 13, 141-142.	2.5	3
45	THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017019.	0.5	34
46	Cryptogenic Stroke. New England Journal of Medicine, 2016, 375, e26.	13.9	52
47	Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 12-20.	0.7	45
48	Mycophenolate Mofetil (MMF)-Induced Colitis. Blood, 2016, 128, 4795-4795.	0.6	7
49	Hospital Volume Does Not Influence in-Hospital Mortality of Autologous Hematopoietic Cell Transplant Among Multiple Myeloma Patients in the United States. Blood, 2016, 128, 392-392.	0.6	0
50	Heparin Reexposure in Patients With a History of Heparin-Induced Thrombocytopenia. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 626-631.	0.7	19
51	Demographic and other characteristics of nodal non-Hodgkin's lymphoma managed in academic <i>versus</i> non-academic centers. Therapeutic Advances in Hematology, 2015, 6, 223-227.	1.1	6
52	New Oral Anticoagulants for the Management of Heparin Induced Thrombocytopenia: A Focused Literature Review. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2015, 13, 87-91.	0.4	8
53	Myxedema Coma with Reversible Cardiopulmonary Failure: a Rare Entity in 21 Century. Mædica, 2015, 10, 268-271.	0.4	0
54	Tuberous sclerosis complex with autosomal dominant polycystic kidney disease: a rare duo. BMJ Case Reports, 2014, 2014, bcr2014207471-bcr2014207471.	0.2	11

#	Article	IF	CITATIONS
55	Exertional Chest Pain and Dyspnea From Hyperviscosity Syndrome Related to Marginal Zone Lymphoma. World Journal of Oncology, 2014, 5, 175-177.	0.6	0
56	Aortic dissection as a rare complication of percutaneous coronary intervention. BMJ Case Reports, 2014, 2014, bcr2014206414-bcr2014206414.	0.2	0